Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.

Abstract

The introduction of molecularly targeted drugs has increased the risk of reactivation of hepatitis B virus (HBV), which is a potentially fatal complication following anticancer chemotherapy even in patients who have previously resolved their HBV infection. CC chemokine receptor 4 (CCR4) has been identified as a novel molecular target in antibody therapy for patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma, and the humanized anti-CCR4 monoclonal antibody mogamulizumab has been developed. We reported HBV reactivation of an ATL patient with previously resolved HBV infection after mogamulizumab treatment in a dose-finding study for this antibody. Our retrospective analysis using preserved samples also revealed the detailed kinetics of HBV DNA levels before and just after HBV reactivation.

• Authors: Nobuaki Nakano, Shigeru Kusumoto, Yasuhito Tanaka, Takashi Ishida, Shogo Takeuchi, Yoshifusa Takatsuka, Shiro Akinaga, Masashi Mizokami, Ryuzo Ueda, Atae Utsunomiya
• Journal: Hepatology research : the official journal of the Japan Society of Hepatology (Hepatol Res) Vol. 44 Issue 3 Pg. 354-7 (Mar 2014) ISSN: 1386-6346 [Print] Netherlands
• PMID: 23601025 (Publication Type: Journal Article)
• Copyright: © 2013 The Japan Society of Hepatology.